The role of fosfomycin in the management of urinary tract infections


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article analyses major guidelines on the management of uncomplicated cystitis. The authors outline and substantiate the role of fosfomycin in the management of urinary tract infections. They provide current evidence on the resistance of uropathogens, including those producing extended-spectrum β-lactamase. Combination therapy (fosfomycin + β-lactams or aminoglycosides) is often used to treat infections caused by multiresistant microorganisms. The possibility of using fosfomycin for perioperative prophylaxis of UTI during endourologic operations and transrectal prostate biopsy is shown.

Full Text

Restricted Access

About the authors

A. V Zaitsev

A.I. Evdokimov MSUMD of Minzdrav of Russia

Email: zaitcevandrew@mail.ru
Dr.Med.Sci., Prof. at the Department of Urology

K. B Kolontarev

A.I. Evdokimov MSUMD of Minzdrav of Russia

Dr.Med.Sci., Department of Urology

References

  1. European Association of Urology Guidelines on Urological Infections. www.uroweb.org
  2. Naber K.G., Schito G., Botto H., Palou J., Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54(5):1164-1175.
  3. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Шевелев А.Н., Гринев А.В., Перепанова Т.С., Козлов Р.С., исследовательская группа «ДАРМИС». Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010-2011). Клиническая микробиология и антимикробная химиотерапия. 2012;14 (4):280-302
  4. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М., 2017
  5. Лоран О.Б., Петров С.Б., Синякова Л.А., Перепанова Т.С., Винаров А.З., Косова И.В. Эффективность применения фосфомицина трометамола (Монурала 3 г) в лечении больных хроническим рецидивирующим циститом. Эффективная фармакотерапия в урологии. 2008;4:14-16
  6. Колонтарев К.Б., Зайцев А.В., Пушкарь Д.Ю. Сравнительный анализ антибактериальной терапии острого цистита. Урология. 2013;3:112-122
  7. Зайцев А.В., Колонтарев К.Б. Неосложненный цистит у женщин. Решенная проблема или необходимость оптимизации лечебной тактики. Эффективная фармакотерапия в акушерстве и гинекологии. 2009;7
  8. Пушкарь Д.Ю., Зайцев А.В., Касян Г.Р., Цыбуля О.А. Обзор препаратов для лечения неосложненного цистита у женщин. Медицинский совет. 2010;7-8:60-66
  9. Зайцев А.В., Тупикина Н.В. Рецидивирующая инфекция мочевых путей - междисциплинарная проблема. Медицинский совет. 2014;19 (Урология):36-44
  10. Naber K.G., Алиджанов Ж.Ф. Существуют ли альтернативные методы антибактериальной терапии и профилактики неосложненных инфекций мочевыводящих путей? Урология. 2014 6:5-13
  11. Ибишев Х.С. Некоторые аспекты лечения персистирующей инфекции нижних мочевыводящих путей у женщин. Урология. 2014;5:30-34
  12. Кульчавеня Е.В., Чередниченко А.Г., Неймарк А.И., Шевченко С.Ю. Частота встречаемости госпитальных уропатогенов и динамика их чувствительности. 2015;2:13-16
  13. Неймарк А.И., Раздорская М.В., Неймарк Б.А. Комплексное лечение хронического цистита у женщин. Урология. 2016;4:24-28
  14. Michalopoulos A.S., Livaditis I.G., Gougoutas V. The revival of fosfomycin. Int J. Infect Dis 2011;15(11):e732-739.
  15. Naber K.G. Fosfomycin trometamol in treatment of uncomplicated lower urinary tract infections in adult women - an overview. Infection 1992;20(Suppl 4):S310-312.
  16. Rodrigo Batista Souza, Daisson José Trevisola, Fabiana Schuelter-Trevisol. Bacterial sensitivity to fosfomycin in pregnant women with urinary infection. Braz J. Infect Dis. 2015;19(3):319-23. Doi: 10.1016/j. bjid.2014.12.009.
  17. Iarikov D., Wassel R., Farley J., Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infect Dis Ther. 2015;4(4):433-58. doi: 10.1007/s40121-015-0092-8.
  18. Minassian M.A., Lewis D.A., Chattopadhyay D. et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J. Antimicrob Agents. 1998;10(1):39-47.
  19. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864-1872.
  20. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J. Antimicrob Chemother. 2010;65(9):1862-77. doi: 10.1093/jac/dkq237.
  21. Falagas M.E., Vouloumanou E.K., Samonis G., Vardakas K.Z. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-47. doi: 10.1128/CMR.00068-15.
  22. Malmartel A., Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur J. Clin Microbiol Infect Dis. 2016;35(3):447-51. doi: 10.1007/s10096-015-2560-1.
  23. McIsaac W.J., Moineddin R., Meaney C., Mazzulli T. Antibiotic-resistant Escherichia coli in women with acute cystitis in Canada. Can J. Infect Dis Med Microbiol. 2013;24(3):143-149.
  24. Sun F., Chen S., Qiu X., Sun Y., Feng W., Chen J., Xia P. Antibacterial activity of fosfomycin against uropathogens. Chemotherapy. 2014;60:157-161.
  25. Neuner E.A., Sekeres J., Hall G.S., van Duin D. Experience with fosfomycin for treatment ofurinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56:5744-5748.
  26. Sastry S., Clarke L.G., Alrowais H., Querry A.M., Shutt K.A., Doi Y. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. Antimicrob Agents Chemother. 2015;59(12):7355-7361. Doi: 10.1128/ AAC.01071-15.
  27. Giancola S.E., Mahoney M.V., Hogan M.D., Raux B.R., McCoy C., Hirsch E.B. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes. Chemotherapy 2017;62:100-104. doi: 10.1159/00.
  28. Matthews P.C., Barrett L.K., Warren S., Stoesser N., Snelling M., Scarborough M., Jones N. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infectious Diseases. 2016;16:556.
  29. Veve M.P., Wagner J.L., Kenney R.M. Grunwald J.L., Davis S.L. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum ß-lactamase urinary tract infections. Int J. Antimicrob Agents. 2016;48(1):56-60. Doi: 10.1016/j. ijantimicag.2016.04.014. Epub 2016 May 12.
  30. Grabein B., Graninger W., Rodríguez Baño J., Dinh A., Liesenfeld D.B. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clinical Microbiology and Infection.2017;23(363):e372.
  31. Asuphon O., Montakantikul P., Houngsaitong J., Kiratisin P., Sonthisombat P. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamics (PK/PD) simulation. Int J. Infect Dis. 2016;50:23-29.
  32. Seija V., Medina Presentado J.C., Bado I. et al. Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review. Int J. Infect Dis. 2015;30:20-26.
  33. Liao Y., Hu G.H., Xu Y.F., Che J.P., Luo M., Zhang H.M., Peng B., Yao X.D., Zheng J.H., Liu M. Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae. Exp Ther Med. 2017;13(3):1003-1010.
  34. Wagenlehner F.M., Thomas P.M., Naber K.G. Fosfomycin trometamol (3,000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: a narrative review. Urol Int. 2014;92(2):125-30. doi: 10.1159/000355103. Epub 2013 Sep 13.
  35. Cai T., Gallelli L., Cocci A. et al. Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J. Urol. 2017;35(2):221-228. doi: 10.1007/s00345-016-1867-6. Epub 2016 May 31.
  36. Fahmy A.M., Kotb A., Youssif T.A., Abdeldiam H., Algebaly O., Elabbady A. Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study. Arab J. Urol. 2016; 14(3):228-33. doi: 10.1016/j.aju.2016.05.003. eCollection 2016 Sep.
  37. Gardiner B.J., Mahony A.A., Ellis A.G., Lawrentschuk N., Bolton D.M., Zeglinski P.T., Frauman A.G., Grayson M.L. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101-05. doi: 10.1093/cid/cit704. Epub 2013 Oct 28.
  38. Cunha B.A., Gran A., Raza M. Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline. Int J. Antimicrob Agents. 2015;45(4):427-29. doi: 10.1016/j.ijantimicag.2014.12.019.
  39. Los-Arcos I., Pigrau C., Rodriguez-Pardo D., Fernândez-Hidalgo N., Andreu A., Larrosa N., Almirante B. Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. Antimicrobial Agents and Chemotherapy. 2016;60(3):1854-1858.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies